Results of the sensitivity analysis—Overall response rate, with 95% confidence interval in square brackets, according to tumor type.

PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics

Margarita Udall
Maria Rizzo
Juliet Kenny
Jim Doherty
SueAnn Dahm
Paul Robbins
Eric Faulkner

February 2018

Abstract Background The programmed death receptor 1 (PD-1) protein is a cell-surface receptor on cer...

Real-world programmed death-ligand 1 prevalence rates in non-small cell lung cancer : correlation with clinicopathological features and tumour mutation status

Holmes, Mikaela
Mahar, Annabelle
Lum, Trina
Kao, Steven Chuan-Hao
Cooper, Wendy A. (R14282)

January 2021

Aims: The detection of programmed death-ligand 1 (PD-L1) protein expression on tumour cells by immun...

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

Carbognin, Luisa
PILOTTO, Sara
BRUNELLI, Matteo
Calio', Anna
CHILOSI, Marco
Bronte, Vincenzo
SCARPA, Aldo
Bria, Emilio
TORTORA, GIAMPAOLO
Milella, Michele
Vaccaro, Vanja
Cuppone, Federica
Sperduti, Isabella
Giannarelli, Diana

January 2015

BACKGROUND:The potential predictive role of programmed death-ligand-1 (PD-L1) expression on tumor ce...

Results of the sensitivity analysis.

Luisa Carbognin (757144)
Sara Pilotto (757145)
Michele Milella (725941)
Vanja Vaccaro (757146)
Matteo Brunelli (295531)
Anna Caliò (295536)
Federica Cuppone (757147)
Isabella Sperduti (85365)
Diana Giannarelli (757148)
Marco Chilosi (295554)
Vincenzo Bronte (234424)
Aldo Scarpa (242345)
Emilio Bria (295532)
Giampaolo Tortora (295546)

June 2015

Panel [A]: overall response rate, with 95% confidence interval in square brackets, accordi...

PD-L1 expression testing in non-small cell lung cancer

Cristina Teixidó
Noelia Vilariño
Roxana Reyes
Noemí Reguart

April 2018

In recent years, immunotherapy has revolutionized and changed the standard of care in patients with ...

Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States.

Vamsidhar Velcheti
Pallavi D Patwardhan
Frank Xiaoqing Liu
Xin Chen
Xiting Cao
Thomas Burke

January 2018

BACKGROUND:The anti-programmed death receptor-1 (anti-PD-1) pembrolizumab is approved as first-line ...

Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC)

Bodor J.
Boumber Y.
Borghaei H.

January 2019

PD-L1 Testing in Cytological Non-Small Cell Lung Cancer Specimens : A Comparison with Biopsies and Review of the Literature

Mansour, Mohammed S I
Lindquist, Kajsa Ericson
Seidal, Tomas
Mager, Ulrich
Mohlin, Rikard
Tran, Lena
Hejny, Kim
Holmgren, Benjamin
Violidaki, Despoina
Dobra, Katalin
Dejmek, Annika
Planck, Maria
Brunnström, Hans

July 2021

INTRODUCTION: Programmed death-ligand 1 (PD-L1) expression is used for treatment prediction in non-s...

Outline of the search—Flow chart of the studies included in the analysis.

Luisa Carbognin (757144)
Sara Pilotto (757145)
Michele Milella (725941)
Vanja Vaccaro (757146)
Matteo Brunelli (295531)
Anna Caliò (295536)
Federica Cuppone (757147)
Isabella Sperduti (85365)
Diana Giannarelli (757148)
Marco Chilosi (295554)
Vincenzo Bronte (234424)
Aldo Scarpa (242345)
Emilio Bria (295532)
Giampaolo Tortora (295546)

June 2015

Pts: patients; n: number; PD-L1: programmed death-ligand-1; IHC: immunohistochemistry; ORR: overa...

Determinants of variability of five programmed death ligand-1 immunohistochemistry assays in non-small cell lung cancer samples.

Soo, RA
Yun Lim, JS
Asuncion, BR
Fazreen, Z
Herrera, MC
Mohd Omar, MF
Diem Phuong, NH
Seet, JE
Amanuel, B
Iacopetta, B
Byrne, D
Hendry, S
Fox, S
Soong, R

January 2018

Programmed death ligand-1 (PD-L1) expression as determined by immunohistochemistry (IHC) is potentia...

The Role of Native T1 and T2 Mapping Times in Identifying PD-L1 Expression and the Histological Subtype of NSCLCs

Bortolotto C.
Messana G.
Lo Tito A.
Stella G. M.
Pinto A.
Podrecca C.
Bellazzi R.
Gerbasi A.
Agustoni F.
Han F.
Nickel M. D.
Zaca D.
Filippi A. R.
Bottinelli O. M.
Preda L.

January 2023

We investigated the association of T1/T2 mapping values with programmed death-ligand 1 protein (PD-L...

Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer

Dhar, Manjima
Wong, Jessica
Che, James
Matsumoto, Melissa
Grogan, Tristan
Elashoff, David
Garon, Edward B
Goldman, Jonathan W
Sollier Christen, Elodie
Di Carlo, Dino
Kulkarni, Rajan P

January 2018

Metastatic non-small cell lung cancer (NSCLC) is a highly fatal and immunogenic malignancy. Although...

Intra- and interobserver reproducibility assessment of PD-L1 biomarker in non-small cell lung cancer

Cooper, Wendy A. (R14282)
Russell, Prudence A.
Cherian, Maya
Duhig, Edwina E.
Godbolt, David
Jessup, Peter J.
Khoo, Christine
Leslie, Connull
Mahar, Annabelle
Moffat, David
Sivasubramaniam, Vanathi
Faure, Celine
Reznichenko, Alena
Grattan, Amanda
Fox, Stephen B.

January 2017

Purpose: Reliable and reproducible methods for identifying PD-L1 expression on tumor cells are neces...

Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients.

Pabla, Sarabjot
Conroy, Jeffrey M
Nesline, Mary K
Glenn, Sean T
Papanicolau-Sengos, Antonios
Burgher, Blake
Hagen, Jacob
Giamo, Vincent
Andreas, Jonathan
Lenzo, Felicia L
Yirong, Wang
Dy, Grace K
Yau, Edwin
Early, Amy
Chen, Hongbin
Bshara, Wiam
Madden, Katherine G
Shirai, Keisuke
Dragnev, Konstantin
Tafe, Laura J
Marin, Daniele
Zhu, Jason
Clarke, Jeff
Labriola, Matthew
McCall, Shannon
Zhang, Tian
Zibelman, Matthew
Ghatalia, Pooja
Araujo-Fernandez, Isabel
Singavi, Arun
George, Ben
MacKinnon, Andrew Craig
Thompson, Jonathan
Singh, Rajbir
Jacob, Robin
Dressler, Lynn
Steciuk, Mark
Binns, Oliver
Kasuganti, Deepa
Shah, Neel
Ernstoff, Marc
Odunsi, Kunle
Kurzrock, Razelle
Gardner, Mark
Galluzzi, Lorenzo
Morrison, Carl

February 2019

Resistance to immune checkpoint inhibitors (ICIs) has been linked to local immunosuppression indepen...

Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): Sensitivity analysis of trials in melanoma, lung and genitourinary cancers

Carbognin, Luisa
Pilotto, Sara
Milella, Michele
Vaccaro, Vanja
Brunelli, Matteo
Caliò, Anna
Cuppone, Federica
Sperduti, Isabella
Giannarelli, Diana
Chilosi, Marco
Bronte, Vincenzo
Scarpa, Aldo
Bria, Emilio (ORCID:0000-0002-2333-704X)
Tortora, Giampaolo (ORCID:0000-0002-1378-4962)

January 2015

Background: The potential predictive role of programmed death-ligand-1 (PD-L1) expression on tumor c...

PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics

Margarita Udall
Maria Rizzo
Juliet Kenny
Jim Doherty
SueAnn Dahm
Paul Robbins
Eric Faulkner

February 2018

Abstract Background The programmed death receptor 1 (PD-1) protein is a cell-surface receptor on cer...

Real-world programmed death-ligand 1 prevalence rates in non-small cell lung cancer : correlation with clinicopathological features and tumour mutation status

Holmes, Mikaela
Mahar, Annabelle
Lum, Trina
Kao, Steven Chuan-Hao
Cooper, Wendy A. (R14282)

January 2021

Aims: The detection of programmed death-ligand 1 (PD-L1) protein expression on tumour cells by immun...

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

Carbognin, Luisa
PILOTTO, Sara
BRUNELLI, Matteo
Calio', Anna
CHILOSI, Marco
Bronte, Vincenzo
SCARPA, Aldo
Bria, Emilio
TORTORA, GIAMPAOLO
Milella, Michele
Vaccaro, Vanja
Cuppone, Federica
Sperduti, Isabella
Giannarelli, Diana

January 2015

BACKGROUND:The potential predictive role of programmed death-ligand-1 (PD-L1) expression on tumor ce...

Results of the sensitivity analysis.

Luisa Carbognin (757144)
Sara Pilotto (757145)
Michele Milella (725941)
Vanja Vaccaro (757146)
Matteo Brunelli (295531)
Anna Caliò (295536)
Federica Cuppone (757147)
Isabella Sperduti (85365)
Diana Giannarelli (757148)
Marco Chilosi (295554)
Vincenzo Bronte (234424)
Aldo Scarpa (242345)
Emilio Bria (295532)
Giampaolo Tortora (295546)

June 2015

Panel [A]: overall response rate, with 95% confidence interval in square brackets, accordi...

PD-L1 expression testing in non-small cell lung cancer

Cristina Teixidó
Noelia Vilariño
Roxana Reyes
Noemí Reguart

April 2018

In recent years, immunotherapy has revolutionized and changed the standard of care in patients with ...

Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States.

Vamsidhar Velcheti
Pallavi D Patwardhan
Frank Xiaoqing Liu
Xin Chen
Xiting Cao
Thomas Burke

January 2018

BACKGROUND:The anti-programmed death receptor-1 (anti-PD-1) pembrolizumab is approved as first-line ...

Biomarkers for immune checkpoint inhibition in non–small cell lung cancer (NSCLC)

Bodor J.
Boumber Y.
Borghaei H.

January 2019

PD-L1 Testing in Cytological Non-Small Cell Lung Cancer Specimens : A Comparison with Biopsies and Review of the Literature

Mansour, Mohammed S I
Lindquist, Kajsa Ericson
Seidal, Tomas
Mager, Ulrich
Mohlin, Rikard
Tran, Lena
Hejny, Kim
Holmgren, Benjamin
Violidaki, Despoina
Dobra, Katalin
Dejmek, Annika
Planck, Maria
Brunnström, Hans

July 2021

INTRODUCTION: Programmed death-ligand 1 (PD-L1) expression is used for treatment prediction in non-s...

Outline of the search—Flow chart of the studies included in the analysis.

Luisa Carbognin (757144)
Sara Pilotto (757145)
Michele Milella (725941)
Vanja Vaccaro (757146)
Matteo Brunelli (295531)
Anna Caliò (295536)
Federica Cuppone (757147)
Isabella Sperduti (85365)
Diana Giannarelli (757148)
Marco Chilosi (295554)
Vincenzo Bronte (234424)
Aldo Scarpa (242345)
Emilio Bria (295532)
Giampaolo Tortora (295546)

June 2015

Pts: patients; n: number; PD-L1: programmed death-ligand-1; IHC: immunohistochemistry; ORR: overa...

Determinants of variability of five programmed death ligand-1 immunohistochemistry assays in non-small cell lung cancer samples.

Soo, RA
Yun Lim, JS
Asuncion, BR
Fazreen, Z
Herrera, MC
Mohd Omar, MF
Diem Phuong, NH
Seet, JE
Amanuel, B
Iacopetta, B
Byrne, D
Hendry, S
Fox, S
Soong, R

January 2018

Programmed death ligand-1 (PD-L1) expression as determined by immunohistochemistry (IHC) is potentia...

The Role of Native T1 and T2 Mapping Times in Identifying PD-L1 Expression and the Histological Subtype of NSCLCs

Bortolotto C.
Messana G.
Lo Tito A.
Stella G. M.
Pinto A.
Podrecca C.
Bellazzi R.
Gerbasi A.
Agustoni F.
Han F.
Nickel M. D.
Zaca D.
Filippi A. R.
Bottinelli O. M.
Preda L.

January 2023

We investigated the association of T1/T2 mapping values with programmed death-ligand 1 protein (PD-L...

Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer

Dhar, Manjima
Wong, Jessica
Che, James
Matsumoto, Melissa
Grogan, Tristan
Elashoff, David
Garon, Edward B
Goldman, Jonathan W
Sollier Christen, Elodie
Di Carlo, Dino
Kulkarni, Rajan P

January 2018

Metastatic non-small cell lung cancer (NSCLC) is a highly fatal and immunogenic malignancy. Although...

Intra- and interobserver reproducibility assessment of PD-L1 biomarker in non-small cell lung cancer

Cooper, Wendy A. (R14282)
Russell, Prudence A.
Cherian, Maya
Duhig, Edwina E.
Godbolt, David
Jessup, Peter J.
Khoo, Christine
Leslie, Connull
Mahar, Annabelle
Moffat, David
Sivasubramaniam, Vanathi
Faure, Celine
Reznichenko, Alena
Grattan, Amanda
Fox, Stephen B.

January 2017

Purpose: Reliable and reproducible methods for identifying PD-L1 expression on tumor cells are neces...

Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients.

Pabla, Sarabjot
Conroy, Jeffrey M
Nesline, Mary K
Glenn, Sean T
Papanicolau-Sengos, Antonios
Burgher, Blake
Hagen, Jacob
Giamo, Vincent
Andreas, Jonathan
Lenzo, Felicia L
Yirong, Wang
Dy, Grace K
Yau, Edwin
Early, Amy
Chen, Hongbin
Bshara, Wiam
Madden, Katherine G
Shirai, Keisuke
Dragnev, Konstantin
Tafe, Laura J
Marin, Daniele
Zhu, Jason
Clarke, Jeff
Labriola, Matthew
McCall, Shannon
Zhang, Tian
Zibelman, Matthew
Ghatalia, Pooja
Araujo-Fernandez, Isabel
Singavi, Arun
George, Ben
MacKinnon, Andrew Craig
Thompson, Jonathan
Singh, Rajbir
Jacob, Robin
Dressler, Lynn
Steciuk, Mark
Binns, Oliver
Kasuganti, Deepa
Shah, Neel
Ernstoff, Marc
Odunsi, Kunle
Kurzrock, Razelle
Gardner, Mark
Galluzzi, Lorenzo
Morrison, Carl

February 2019

Resistance to immune checkpoint inhibitors (ICIs) has been linked to local immunosuppression indepen...

Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): Sensitivity analysis of trials in melanoma, lung and genitourinary cancers

Carbognin, Luisa
Pilotto, Sara
Milella, Michele
Vaccaro, Vanja
Brunelli, Matteo
Caliò, Anna
Cuppone, Federica
Sperduti, Isabella
Giannarelli, Diana
Chilosi, Marco
Bronte, Vincenzo
Scarpa, Aldo
Bria, Emilio (ORCID:0000-0002-2333-704X)
Tortora, Giampaolo (ORCID:0000-0002-1378-4962)

January 2015

Background: The potential predictive role of programmed death-ligand-1 (PD-L1) expression on tumor c...

PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics

Margarita Udall
Maria Rizzo
Juliet Kenny
Jim Doherty
SueAnn Dahm
Paul Robbins
Eric Faulkner

February 2018

Abstract Background The programmed death receptor 1 (PD-1) protein is a cell-surface receptor on cer...

Real-world programmed death-ligand 1 prevalence rates in non-small cell lung cancer : correlation with clinicopathological features and tumour mutation status

Holmes, Mikaela
Mahar, Annabelle
Lum, Trina
Kao, Steven Chuan-Hao
Cooper, Wendy A. (R14282)

January 2021

Aims: The detection of programmed death-ligand 1 (PD-L1) protein expression on tumour cells by immun...

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers

Carbognin, Luisa
PILOTTO, Sara
BRUNELLI, Matteo
Calio', Anna
CHILOSI, Marco
Bronte, Vincenzo
SCARPA, Aldo
Bria, Emilio
TORTORA, GIAMPAOLO
Milella, Michele
Vaccaro, Vanja
Cuppone, Federica
Sperduti, Isabella
Giannarelli, Diana

January 2015

BACKGROUND:The potential predictive role of programmed death-ligand-1 (PD-L1) expression on tumor ce...

Results of the sensitivity analysis—Overall response rate, with 95% confidence interval in square brackets, according to tumor type.

Abstract

Extracted data

Results of the sensitivity analysis—Overall response rate, with 95% confidence interval in square brackets, according to tumor type.

Abstract

Extracted data

Related items

Related items